LA
ABBV icon

Lynch & Associates’s AbbVie ABBV Stock Holding History

Lynch & Associates’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.4M Sell
69,077
-764
-1% -$164K 3.04% 6
2026
Q1 		$15.2M Buy
69,841
+69
+0.1% +$15.3K 2.85% 8
2025
Q4 		$15.9M Sell
69,772
-774
-1% -$176K 3.01% 7
2025
Q3 		$16.3M Sell
70,546
-2,815
-4% -$573K 3.15% 7
2025
Q2 		$13.6M Buy
73,361
+754
+1% +$140K 2.74% 9
2025
Q1 		$15.2M Sell
72,607
-855
-1% -$166K 3.29% 5
2024
Q4 		$13.1M Sell
73,462
-17
-0% -$3.13K 2.83% 7
2024
Q3 		$14.5M Sell
73,479
-267
-0.4% -$49.8K 3.07% 7
2024
Q2 		$12.6M Buy
73,746
+2,731
+4% +$452K 2.85% 8
2024
Q1 		$12.9M Sell
71,015
-4,443
-6% -$766K 2.99% 7
2023
Q4 		$11.7M Sell
75,458
-1,415
-2% -$206K 2.84% 7
2023
Q3 		$11.5M Buy
76,873
+327
+0.4% +$48K 3.02% 8
2023
Q2 		$10.3M Sell
76,546
-1,257
-2% -$184K 2.64% 10
2023
Q1 		$12.4M Sell
77,803
-1,935
-2% -$296K 3.25% 7
2022
Q4 		$12.9M Sell
79,738
-365
-0.5% -$56K 3.37% 7
2022
Q3 		$10.8M Sell
80,103
-1,258
-2% -$181K 3.15% 7
2022
Q2 		$12.5M Buy
81,361
+109
+0.1% +$16.7K 3.39% 6
2022
Q1 		$13.2M Sell
81,252
-1,518
-2% -$221K 3.19% 7
2021
Q4 		$11.2M Buy
82,770
+110
+0.1% +$13K 2.65% 8
2021
Q3 		$8.92M Buy
82,660
+15
+0% +$1.71K 2.31% 10
2021
Q2 		$9.31M Buy
82,645
+59
+0.1% +$6.64K 2.39% 9
2021
Q1 		$8.94M Buy
82,586
+1,250
+2% +$134K 2.41% 9
2020
Q4 		$8.71M Sell
81,336
-480
-0.6% -$46.1K 2.37% 9
2020
Q3 		$7.17M Buy
81,816
+8,290
+11% +$780K 2.15% 12
2020
Q2 		$7.22M Sell
73,526
-1,107
-1% -$97.5K 2.34% 10
2020
Q1 		$5.69M Sell
74,633
-1,376
-2% -$117K 2.09% 12
2019
Q4 		$6.73M Buy
76,009
+3,475
+5% +$288K 1.93% 15
2019
Q3 		$5.49M Sell
72,534
-1,224
-2% -$83.9K 1.68% 24
2019
Q2 		$5.36M Sell
73,758
-133
-0.2% -$10.5K 1.74% 24
2019
Q1 		$5.96M Sell
73,891
-929
-1% -$76K 1.97% 18
2018
Q4 		$6.9M Buy
74,820
+18,516
+33% +$1.63M 2.58% 11
2018
Q3 		$5.33M Sell
56,304
-3,790
-6% -$359K 1.8% 21
2018
Q2 		$5.57M Buy
60,094
+1,037
+2% +$101K 2.02% 17
2018
Q1 		$5.59M Sell
59,057
-3,522
-6% -$387K 2.14% 13
2017
Q4 		$6.05M Sell
62,579
-366
-0.6% -$34.5K 2.27% 12
2017
Q3 		$5.59M Buy
62,945
+787
+1% +$59.9K 2.22% 14
2017
Q2 		$4.51M Buy
62,158
+2,948
+5% +$198K 1.78% 16
2017
Q1 		$3.86M Sell
59,210
-3,987
-6% -$251K 1.57% 21
2016
Q4 		$3.96M Buy
63,197
+1,738
+3% +$106K 1.67% 19
2016
Q3 		$3.88M Sell
61,459
-996
-2% -$64.5K 1.71% 16
2016
Q2 		$3.87M Buy
62,455
+2,585
+4% +$158K 1.73% 18
2016
Q1 		$3.42M Sell
59,870
-794
-1% -$44.3K 1.63% 18
2015
Q4 		$3.59M Buy
60,664
+237
+0.4% +$13.7K 1.84% 16
2015
Q3 		$3.29M Sell
60,427
-34
-0.1% -$2.21K 1.82% 17
2015
Q2 		$4.06M Buy
60,461
+2,010
+3% +$131K 2.12% 14
2015
Q1 		$3.42M Buy
58,451
+825
+1% +$49.8K 1.8% 19
2014
Q4 		$3.77M Sell
57,626
-173
-0.3% -$10.9K 2.03% 14
2014
Q3 		$3.34M Buy
57,799
+3,052
+6% +$169K 1.88% 15
2014
Q2 		$3.09M Buy
54,747
+158
+0.3% +$8.29K 1.76% 19
2014
Q1 		$2.81M Buy
54,589
+1,061
+2% +$53.6K 1.66% 23
2013
Q4 		$2.83M Buy
53,528
+1,611
+3% +$79.2K 1.69% 20
2013
Q3 		$2.32M Buy
51,917
+536
+1% +$23.8K 1.55% 23
2013
Q2 		$2.12M Buy
+51,381
New +$2.25M 1.47% 23

Other funds holding ABBV

LMFP
Larry Mathis Financial Planning Phoenix, Arizona $124B AUM
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
HCM
Hamlin Capital Management New York $4.45B AUM 22.95% 1-Year Est. Return
AAMU
AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return
HPC
HM Payson & Co Portland, Maine $7.54B AUM 31.34% 1-Year Est. Return
CRM
Cardano Risk Management Rotterdam, Netherlands $13B AUM 49.44% 1-Year Est. Return
CNB
Czech National Bank Prague, Czech Republic $18.3B AUM 43.04% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Lynch & Associates's ABBV Position: Q2 2026 in Review

Lynch & Associates reduced its AbbVie (ABBV) stake by 1.1% in Q2 2026, selling an estimated $164K and leaving 69,077 shares worth $17.4M. The position accounts for 3.04% of the portfolio, ranked #6.

Lynch & Associates first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. 803 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Lynch & Associates held 69,077 shares of AbbVie worth $17.4M as of Q2 2026.
  • Lynch & Associates sold 764 AbbVie shares in Q2 2026, an estimated $164K.
  • AbbVie made up 3.04% of Lynch & Associates's portfolio in Q2 2026, its #6 holding.
  • Lynch & Associates first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
  • 803 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Lynch & Associates's 13F filing for Q2 2026, filed 13 Jul 2026.